Although indacaterol has a higher IC50 on L858R/T790M EGFR-bearing NSCLC cells (~14 μM), as compared with a third-generation irreversible mutant-selective EGFR TKI (osimertinib) (~11 nM) (15), the concentration may be achievable for a locally administered drug. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.